Jardiance Vs Farxiga: this caregiver-focused guide explains what jardiance vs farxiga means in plain English, the day-to-day implications for families, and when to bring it up with a clinician. If you arrived here looking for a quick orientation on jardiance vs farxiga, the table of contents below points to the section you need; the full guide picks up after it.
Table of contents
- Table of Contents
- What Are the Key Differences Between Jardiance and Farxiga as SGLT2 Inhibitors?
- Heart Failure and Cardiovascular Protection — Where the Two Drugs Split
- Chronic Kidney Disease — Farxiga Got There First
- Cost and Generic Availability — A Practical Comparison That Matters
- Side Effects and Safety Warnings — What to Watch For
- SGLT2 Inhibitors and Brain Health — An Emerging Research Area
- The Future of SGLT2 Inhibitors — What Comes Next
Neither Jardiance nor Farxiga is definitively better than the other — the right choice depends on your specific health conditions, insurance coverage, and treatment priorities. If cardiovascular death reduction is the primary concern, Jardiance has a distinct FDA-approved edge. If you need broader heart failure coverage across all ejection fraction types or want a lower-cost generic option, Farxiga pulls ahead. For the millions of Americans managing type 2 diabetes alongside heart or kidney disease, understanding these differences is not academic — it directly shapes outcomes.
Both drugs belong to the SGLT2 inhibitor class, which works by blocking glucose reabsorption in the kidneys and flushing excess sugar out through urine. Jardiance (empagliflozin), made by Boehringer Ingelheim and Eli Lilly, and Farxiga (dapagliflozin), made by AstraZeneca, have become two of the most prescribed medications in this rapidly growing drug class — a market valued at $16.8 billion in 2024 and projected to reach $28.9 billion by 2033. This article breaks down how they compare on blood sugar control, heart protection, kidney benefits, side effects, and cost so you can have a more informed conversation with your doctor. For readers on this site particularly concerned with brain health, this comparison matters because cardiovascular health and kidney function are closely tied to cognitive outcomes. Poor blood sugar control, heart failure, and chronic kidney disease all increase dementia risk, making the choice between these two medications relevant well beyond glucose numbers on a lab report.
Table of Contents
- What Are the Key Differences Between Jardiance and Farxiga as SGLT2 Inhibitors?
- Heart Failure and Cardiovascular Protection — Where the Two Drugs Split
- Chronic Kidney Disease — Farxiga Got There First
- Cost and Generic Availability — A Practical Comparison That Matters
- Side Effects and Safety Warnings — What to Watch For
- SGLT2 Inhibitors and Brain Health — An Emerging Research Area
- The Future of SGLT2 Inhibitors — What Comes Next
- Conclusion
- Frequently Asked Questions
What Are the Key Differences Between Jardiance and Farxiga as SGLT2 Inhibitors?
On paper, Jardiance and Farxiga look nearly identical. Both lower HbA1c by roughly the same amount — Jardiance reduces it by up to 1.0% after 24 weeks, while Farxiga brings it down by about 0.9%. No head-to-head clinical trial has ever been conducted between the two, so claims that one is more effective at lowering blood sugar than the other are based on separate studies with different patient populations. In practical terms, their glucose-lowering power is considered comparable by most endocrinologists. Where they diverge is in their FDA-approved indications.
Jardiance is the only SGLT2 inhibitor approved for pediatric use in type 2 diabetes patients ages 10 and older — a meaningful distinction for families dealing with childhood-onset diabetes. Farxiga, on the other hand, is only approved for adults with type 2 diabetes. Jardiance comes in 10mg and 25mg tablets, while Farxiga is available in 5mg and 10mg doses. These dosing differences matter when physicians need to titrate carefully, particularly in older patients or those with fluctuating kidney function. The most significant clinical distinction sits in the cardiovascular and kidney disease approvals, which is where the real decision-making happens for most patients. These differences are not trivial — they reflect different trial designs, different patient populations studied, and different regulatory milestones that have real consequences for which drug your insurance will cover for a given condition.
Heart Failure and Cardiovascular Protection — Where the Two Drugs Split
Jardiance holds a unique FDA-approved indication for reducing cardiovascular death in type 2 diabetes patients with established cardiovascular disease, based on the landmark EMPA-REG OUTCOME trial. No other SGLT2 inhibitor has this specific approval. For a patient who has already had a heart attack or been diagnosed with significant cardiovascular disease alongside their diabetes, this approval carries weight — it means the drug was specifically studied and proven effective in that high-risk population. However, if heart failure itself is the primary concern rather than cardiovascular death specifically, Farxiga has the broader label. Farxiga is approved for heart failure across all ejection fraction types, meaning it covers both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction.
Jardiance’s heart failure approval is limited to reduced ejection fraction only. This distinction matters enormously for the large number of older adults — particularly women — who develop heart failure with preserved ejection fraction, a condition that has historically had few effective treatments. A large observational study of more than 280,000 patients found that both drugs were equally effective at reducing the risk of serious cardiovascular events like heart attack and stroke. But Jardiance showed a slight advantage for heart failure hospitalization — patients on low-dose Farxiga (5mg) had a higher risk of being hospitalized for heart failure compared to those on Jardiance. If you are currently on low-dose Farxiga and have been hospitalized for heart failure, this is worth discussing with your cardiologist, though observational data should always be interpreted cautiously compared to randomized trial results.
Chronic Kidney Disease — Farxiga Got There First
Farxiga was the first SGLT2 inhibitor to receive FDA approval for chronic kidney disease, earning that indication in 2021 based on the DAPA-CKD trial. This was a landmark moment because it established that SGLT2 inhibitors could protect kidneys independently of their blood sugar-lowering effects — even in patients without diabetes. Jardiance followed with its own CKD approval in June 2023, narrowing the gap, but Farxiga’s two-year head start means it has more established real-world data and often greater formulary coverage for kidney disease specifically. For people concerned about brain health, the kidney connection deserves attention. Chronic kidney disease is an independent risk factor for cognitive decline and dementia.
The kidneys and the brain share similar small-vessel architecture, and damage to one often signals damage to the other. By slowing kidney disease progression, SGLT2 inhibitors may offer indirect neuroprotective benefits, though dedicated trials studying cognitive outcomes with these drugs are still in early stages. One important caveat: both drugs become less effective at lowering blood sugar as kidney function declines, because they rely on the kidneys to excrete glucose. Their cardiovascular and kidney-protective benefits appear to persist even in patients with reduced kidney function, but the glucose-lowering effect diminishes. Your doctor will likely monitor your estimated glomerular filtration rate closely and may adjust the role these medications play in your overall diabetes management as kidney function changes.
Cost and Generic Availability — A Practical Comparison That Matters
Cost is often the deciding factor, and here Farxiga has a clear advantage. An authorized generic version of dapagliflozin became available in the United States in early 2024, significantly reducing out-of-pocket costs for many patients. Jardiance, by contrast, has no generic version available in the U.S. as of early 2026 and remains brand-name only. At list price, Jardiance runs approximately $629.43 per month for a 30-day supply, while Farxiga lists at roughly $599.72 — but the generic dapagliflozin can cost substantially less than either brand. Both manufacturers offer copay assistance programs.
Farxiga’s copay card can reduce out-of-pocket costs to as low as $0 per month, while Jardiance’s card can bring costs down to $10 per month. These programs typically apply only to commercially insured patients — if you are on Medicare or Medicaid, you generally cannot use manufacturer copay cards, making the generic availability of dapagliflozin even more significant. A Medicare patient choosing between these two drugs may find that generic dapagliflozin saves hundreds of dollars per month compared to brand-name Jardiance. Despite the cost advantage, Jardiance dominates the market with a 55.3% share of all SGLT2 inhibitor prescriptions in 2024. Farxiga generated approximately $4.5 billion in global sales in 2022, with a roughly 25% compound annual growth rate over the preceding three years. The market dynamics suggest that physician familiarity and established prescribing habits still favor Jardiance, but the availability of generic dapagliflozin may gradually shift that balance — particularly as health systems and insurers push toward lower-cost alternatives.
Side Effects and Safety Warnings — What to Watch For
Both Jardiance and Farxiga share a common side effect profile rooted in their mechanism of action. By flushing excess glucose through the urine, they create a sugar-rich environment in the urinary tract that promotes infections. Urinary tract infections and genital yeast infections — particularly in women — are the most frequently reported side effects for both drugs. Increased urination, nausea, and upper respiratory infections also appear commonly in clinical trial data. Farxiga carries an additional warning that Jardiance does not: necrotizing fasciitis of the perineum, also known as Fournier’s gangrene.
This is an extremely rare but life-threatening bacterial infection of the tissue between the genitals and the anus that requires immediate hospitalization and surgical intervention. While the absolute risk is very low, it is a distinct safety signal that the FDA specifically flagged for Farxiga. Both drugs carry warnings for diabetic ketoacidosis, which can occur even when blood sugar levels are not particularly elevated — a phenomenon called euglycemic DKA that can catch patients and even some clinicians off guard. Dehydration and low blood pressure are also concerns with both medications, especially in older adults who may already be taking diuretics or blood pressure medications. For dementia caregivers managing medication for a loved one, this is a practical concern: increased urination combined with cognitive impairment can lead to dehydration if fluid intake is not actively monitored. If the person you are caring for has difficulty communicating thirst or independently accessing fluids, discuss this risk explicitly with their prescribing physician.
SGLT2 Inhibitors and Brain Health — An Emerging Research Area
Researchers are increasingly interested in whether SGLT2 inhibitors might offer direct or indirect neuroprotective effects. The logic is straightforward: these drugs reduce cardiovascular events, lower blood pressure, protect kidneys, and reduce inflammation — all factors that influence brain health and dementia risk.
Several observational studies have suggested that patients taking SGLT2 inhibitors may have lower rates of cognitive decline compared to those on other diabetes medications, though no randomized controlled trial has yet confirmed a direct cognitive benefit. This does not mean you should take Jardiance or Farxiga specifically for brain protection. But if you or a family member already needs an SGLT2 inhibitor for diabetes, heart failure, or kidney disease, the potential cognitive upside is a reasonable factor to mention in a conversation with your neurologist or geriatrician — particularly if dementia risk factors are already present.
The Future of SGLT2 Inhibitors — What Comes Next
The SGLT2 inhibitor class is still expanding its reach. Ongoing clinical trials are investigating these drugs for conditions beyond their current approvals, including liver disease, obesity-related complications, and yes, neurodegenerative conditions. The projected growth of this market to $28.9 billion by 2033 reflects confidence that new indications and broader use will continue.
As more generics enter the market — generic dapagliflozin is already available, and empagliflozin generics will eventually follow — access barriers should continue to fall. For patients and caregivers navigating these choices today, the most important development to watch is whether your insurance formulary changes its preferred SGLT2 inhibitor. Formulary shifts driven by generic availability can happen quickly, and a drug that cost you $10 last month could suddenly cost $200 if your plan switches its preferred agent. Stay in contact with your pharmacist and insurance provider, and do not assume that your current copay will remain stable indefinitely.
Conclusion
Jardiance and Farxiga are both excellent SGLT2 inhibitors with strong evidence behind them, but they are not interchangeable. Jardiance stands out for its cardiovascular death reduction indication and pediatric approval. Farxiga stands out for its broader heart failure coverage across all ejection fraction types, its earlier CKD approval, and the significant cost savings now possible through its authorized generic.
A large observational study of over 280,000 patients found comparable cardiovascular event reduction with both drugs, with Jardiance showing a modest edge in preventing heart failure hospitalizations. The practical decision often comes down to your specific diagnoses, your insurance coverage, and your out-of-pocket costs. Talk with your doctor about which drug aligns with your clinical profile, and talk with your pharmacist about which one your plan actually covers at a reasonable price. For those managing diabetes alongside heart disease, kidney disease, or dementia risk factors, getting the right SGLT2 inhibitor — and being able to afford it consistently — can make a meaningful difference in long-term outcomes.
Frequently Asked Questions
Can I switch from Jardiance to Farxiga or vice versa?
Yes, switching between SGLT2 inhibitors is common and generally straightforward, though your doctor will want to adjust the dose appropriately since the two drugs use different dosing scales. There is usually no washout period needed.
Do Jardiance or Farxiga cause weight loss?
Both drugs are associated with modest weight loss of roughly 2 to 4 pounds, primarily due to calorie loss through glucose excreted in the urine. They are not approved as weight loss medications, and the effect tends to plateau after several months.
Are SGLT2 inhibitors safe for elderly patients with dementia?
They can be, but the increased urination and dehydration risk require careful monitoring, especially in patients who cannot reliably communicate thirst or manage their own fluid intake. A caregiver or family member should be actively involved in hydration monitoring.
Is generic dapagliflozin as effective as brand-name Farxiga?
Yes. Authorized generics contain the same active ingredient, at the same dose, manufactured to the same standards. The FDA requires bioequivalence testing before any generic is approved. There is no clinical reason to prefer the brand over the authorized generic.
Can I take an SGLT2 inhibitor if I have type 1 diabetes?
Neither Jardiance nor Farxiga is FDA-approved for type 1 diabetes. Using SGLT2 inhibitors in type 1 diabetes significantly increases the risk of diabetic ketoacidosis. Some physicians prescribe them off-label with close monitoring, but this carries real risk and should only be done under specialist supervision.
Will a generic version of Jardiance become available soon?
As of early 2026, no generic empagliflozin is available in the United States. Patent timelines suggest a generic could arrive within the next few years, but no specific date has been confirmed. In the meantime, the manufacturer copay card can reduce costs to as low as $10 per month for commercially insured patients.
You Might Also Like
- Zoloft vs. Prozac: Psychiatrists Reveal Which They Actually Prefer
- Metoprolol vs. Atenolol: Which Beta Blocker Is Right for You?
- Atorvastatin vs. Rosuvastatin: Cardiologists Reveal Which Is Better
Sources used for this Jardiance Vs Farxiga guide
- National Institute on Aging — Alzheimer’s and related dementias
- Alzheimer’s Association
- Mayo Clinic — Dementia
This article is informational and not medical advice. See our Editorial Policy for how we research and review content. Last reviewed May 30, 2026.
